Literature DB >> 10660765

Goiter recurrence in patients submitted to thyroid-stimulating hormone suppression: possible role of insulin-like growth factors and insulin-like growth factor-binding proteins.

G Torre1, A Barreca, G Borgonovo, M Minuto, G L Ansaldo, E Varaldo, F Minuto.   

Abstract

BACKGROUND: It is known that factors other than thyroid-stimulating hormone, such as insulin-like growth factor-I (IGF-I) and epidermal growth factor, have a goitrogenic effect. It has been established that insulin-like growth factor-binding proteins (IGFBPs) may play a role as autocrine/paracrine factors in regulating the local actions of IGFs. Both an inhibitory and a stimulatory effect for different IGFBPs have been shown in several cell systems. The aim of this study was to assess the involvement of IGFBPs in the goitrogenic process in patients with goiter recurrence.
METHODS: The IGFBP-1 and -3 content in normal and nodular tissues obtained at the time of thyroidectomy from 10 patients with recurrent goiters, unresponsive to thyroid-stimulating hormone suppressive therapy, was studied. In all patients, a fragment of normal tissue was also obtained. The IGF-I, IGFBP-1, and -3 content was evaluated by specific immunoassays and/or immunoblotting with anti-IGFBP specific antiserum.
RESULTS: The IGF-I content was significantly higher (P < .05) in nodular tissues (8.0 +/- 1.6 ng/g of tissue) than what was found in normal tissue (4.8 +/- 0.9 ng/g). Radioimmunoassay IGFBP-3 concentration in nodular tissue was 111.5 +/- 18.2 ng/g significantly higher (P < .001) than values found in normal tissue (77.5 +/- 18.6 ng/g). By immunoblot, IGFBP-1 appeared higher in all but 1 nodular tissue.
CONCLUSIONS: These data raise the possibility that IGFBPs are important in the proliferative activities entailed in the goitrogenic process. Three mechanisms are potentially involved: (1) reduction of the potency of locally produced IGF peptide to downregulate type I receptors (potentiating effect on the autocrine/paracrine mitogenic action of IGFs); (2) increase of the IGF-I tissue concentration restraining its passage to circulation; and (3) protection of IGF-I from degradation. Further studies are needed to define a more precise link between these factors and the recurrence of goiter.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10660765     DOI: 10.1067/msy.2000.100937

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  11 in total

1.  Five-year follow-up of a randomized clinical trial of total thyroidectomy versus Dunhill operation versus bilateral subtotal thyroidectomy for multinodular nontoxic goiter.

Authors:  Marcin Barczyński; Aleksander Konturek; Alicja Hubalewska-Dydejczyk; Filip Gołkowski; Stanisław Cichoń; Wojciech Nowak
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

Review 2.  Less than total thyroidectomy for goiter: when and how?

Authors:  Özer Makay
Journal:  Gland Surg       Date:  2017-12

3.  Surgery for recurrent goiter: complication rate and role of the thyroid-stimulating hormone-suppressive therapy after the first operation.

Authors:  P Miccoli; G Frustaci; A Fosso; M Miccoli; G Materazzi
Journal:  Langenbecks Arch Surg       Date:  2014-11-29       Impact factor: 3.445

4.  Should subtotal thyroidectomy be abandoned in multinodular goiter patients from endemic regions requiring surgery?

Authors:  Tayfun Yoldas; Ozer Makay; Gokhan Icoz; Timur Kose; Gulten Gezer; Erkan Kismali; Sadık Tamsel; Sureyya Ozbek; Mustafa Yılmaz; Mahir Akyildiz
Journal:  Int Surg       Date:  2015-01

5.  Risk factors for recurrent nodular goiter after thyroidectomy for benign disease: case-control study of 244 patients.

Authors:  Hélène Gibelin; Mauricio Sierra; Denis Mothes; Pierre Ingrand; Pierre Levillain; Corinne Jones; Sammy Hadjadj; Florence Torremocha; Richard Marechaud; Jacques Barbier; Jean-Louis Kraimps
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

6.  Five-year follow-up of a randomized clinical trial of unilateral thyroid lobectomy with or without postoperative levothyroxine treatment.

Authors:  Marcin Barczyński; Aleksander Konturek; Filip Gołkowski; Alicja Hubalewska-Dydejczyk; Stanisław Cichoń; Wojciech Nowak
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

7.  Unilateral thyroidectomy for the treatment of benign multinodular goiter.

Authors:  Philip S Bauer; Sara Murray; Nicholas Clark; David S Pontes; Rebecca S Sippel; Herbert Chen
Journal:  J Surg Res       Date:  2013-05-11       Impact factor: 2.192

Review 8.  Follow-up after surgery for benign nodular thyroid disease: evidence-based approach.

Authors:  Roy Phitayakorn; Christopher R McHenry
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

Review 9.  Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature.

Authors:  Jacob Moalem; Insoo Suh; Quan-Yang Duh
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

10.  Serum levels of insulin-like growth factor 1 are negatively associated with log transformation of thyroid-stimulating hormone in Graves' disease patients with hyperthyroidism or subjects with euthyroidism: A prospective observational study.

Authors:  Fen-Yu Tseng; Yen-Ting Chen; Yu-Chiao Chi; Pei-Lung Chen; Wei-Shiung Yang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.